##common.pageHeaderLogo.altText##
DOI:
https://doi.org/10.57187/4634

Original article

Vol. 156 No. 8 (2026)

Diagnostic and therapeutic gaps in Chronic Obstructive Pulmonary Disease management and their associations with 1-year survival after hospitalisation for acute exacerbations

Cite this as:
Swiss Med Wkly. 2026;156:4634
Published
31.08.2026

Summary

INTRODUCTION AND OBJECTIVES: Chronic Obstructive Pulmonary Disease (COPD) remains a leading cause of morbidity and mortality globally. Acute exacerbations of COPD (AE-COPD) significantly worsen patient outcomes; however, COPD is frequently underdiagnosed and undertreated despite established guidelines.This study aimed to assess (1) the characteristics of patients hospitalised for a first episode of AE-COPD, (2) the differences between patients who had received guideline-recommended inhalation therapy prior to their first AE-COPD hospitalisation and those who had not, and (3) the associations between patient characteristics, pre-hospital inhalation treatment status and 1-year all-cause mortality following the index hospitalisation.

METHODS: In this retrospective cohort study, 1855 consecutive patients admitted with clinically and spirometrically diagnosed AE-COPD to a secondary-level Swiss hospital between September 2016 and September 2024 were analysed. The primary outcome was 1-year all-cause mortality following the index hospitalisation. Survival was analysed using Kaplan-Meier estimates and Cox proportional hazards regression, with results reported as hazard ratios with 95% confidence intervals.

RESULTS: Overall, 50.6% (n = 938) of patients lacked documented spirometric GOLD staging and 82.6% (n = 1533) had no recorded risk classification. Patients were stratified based on pre-admission use of long-acting inhalation therapy: Group 1 (no therapy, n = 834 [45.0%]) and Group 2 (therapy, n = 1021 [55.0%]). Baseline characteristics were largely comparable between groups; however, patients receiving long-acting inhalation therapy (Group 2) had significantly more patients with spirometrically confirmed COPD. During 1-year follow-up, 236 deaths (12.7%) occurred, in 133 of the 834 (15.9%) Group 1 patients and 103 of the 1021 (10.1%) Group 2 patients  (log-rank p <0.001). In multivariable Cox regression analysis, no long-acting inhalation therapy (Group 1) as a variable was independently associated with higher 1-year all-cause mortality (adjusted HR: 1.95, CI: 1.48–2.56, p <0.001).

CONCLUSION: Significant diagnostic and therapeutic gaps were observed in patients hospitalised for the first episode of AE-COPD. Guideline-recommended inhalation therapy prior to hospitalisation was independently associated with decreased 1-year all-cause mortality. Our findings suggest that guideline-recommended inhalation therapy reflects structured COPD care, earlier diagnosis and closer medical follow-up rather than a pharmacological effect alone. Hospitalisation for AE-COPD represents a critical opportunity to reassess the diagnosis and optimise long-term management, even within a well-resourced healthcare system.

References

  1. 1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006 Nov;3(11):e442. 10.1371/journal.pmed.0030442
  2. 2. Rehman AU, Hassali MA, Muhammad SA, Harun SN, Shah S, Abbas S. The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature. Eur J Health Econ. 2020 Mar;21(2):181–94. 10.1007/s10198-019-01119-1
  3. 3. Vogelmeier CF, Román-Rodríguez M, Singh D, Han MK, Rodríguez-Roisin R, Ferguson GT. Goals of COPD treatment: focus on symptoms and exacerbations. Respir Med. 2020 May;166:105938. 10.1016/j.rmed.2020.105938
  4. 4. Dransfield MT, Kunisaki KM, Strand MJ, Anzueto A, Bhatt SP, Bowler RP, et al.; COPDGene Investigators. Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017 Feb;195(3):324–30. 10.1164/rccm.201605-1014OC
  5. 5. Guay CA, Maltais F, Beaudoin C, Carmichael PH, Laouan Sidi EA, Perreault L, et al. Trends in COPD severe exacerbations, and all-cause and respiratory mortality, before and after implementation of newer long-acting bronchodilators in a large population-based cohort. BMC Pulm Med. 2024 Sep;24(1):450. 10.1186/s12890-024-03277-2
  6. 6. Sandelowsky H, Weinreich UM, Aarli BB, Sundh J, Høines K, Stratelis G, et al. COPD - do the right thing. BMC Fam Pract. 2021 Dec;22(1):244. 10.1186/s12875-021-01583-w
  7. 7. Diab N, Gershon AS, Sin DD, Tan WC, Bourbeau J, Boulet LP, et al. Underdiagnosis and Overdiagnosis of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2018 Nov;198(9):1130–9. 10.1164/rccm.201804-0621CI
  8. 8. Peña VS, Miravitlles M, Gabriel R, Jiménez-Ruiz CA, Villasante C, Masa JF, et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest. 2000 Oct;118(4):981–9. 10.1378/chest.118.4.981
  9. 9. Axelsson M, Backman H, Nwaru BI, Stridsman C, Vanfleteren L, Hedman L, et al. Underdiagnosis and misclassification of COPD in Sweden - A Nordic Epilung study. Respir Med. 2023 Oct;217:107347. 10.1016/j.rmed.2023.107347
  10. 10. Martinez CH, Mannino DM, Jaimes FA, Curtis JL, Han MK, Hansel NN, et al. Undiagnosed Obstructive Lung Disease in the United States. Associated Factors and Long-term Mortality. Ann Am Thorac Soc. 2015 Dec;12(12):1788–95. 10.1513/AnnalsATS.201506-388OC
  11. 11. Halpin DM, Miravitlles M, Metzdorf N, Celli B. Impact and prevention of severe exacerbations of COPD: a review of the evidence. Int J Chron Obstruct Pulmon Dis. 2017 Oct;12:2891–908. 10.2147/COPD.S139470
  12. 12. Boesing M, Ottensarendt N, Lüthi-Corridori G, Leuppi JD. The Management of Acute Exacerbations in COPD: A Retrospective Observational Study and Clinical Audit. J Clin Med. 2023 Dec;13(1):19. doi: https://doi.org/10.3390/jcm13010019
  13. 13. Strengthening the reporting of observational studies in epidemiology. STROBE Checklists: STROBE; 2024 [04.02.2025]. Available from: https://www.strobe-statement.org/checklists/
  14. 14. Chen PK, Hsiao YH, Pan SW, Su KC, Perng DW, Ko HK. Independent factors associate with hospital mortality in patients with acute exacerbation of chronic obstructive pulmonary disease requiring intensive care unit admission: focusing on the eosinophil-to-neutrophil ratio. PLoS One. 2019 Jul;14(7):e0218932. 10.1371/journal.pone.0218932
  15. 15. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. 2003 Aug;124(2):459–67. doi: https://doi.org/10.1378/chest.124.2.459
  16. 16. Gunen H, Hacievliyagil SS, Kosar F, Mutlu LC, Gulbas G, Pehlivan E, et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J. 2005 Aug;26(2):234–41. doi: https://doi.org/10.1183/09031936.05.00024804
  17. 17. Montagnani A, Mathieu G, Pomero F, Bertù L, Manfellotto D, Campanini M, et al.; FADOI-Epidemiological Study Group. Hospitalization and mortality for acute exacerbation of chronic obstructive pulmonary disease (COPD): an Italian population-based study. Eur Rev Med Pharmacol Sci. 2020 Jun;24(12):6899–907.
  18. 18. Statulator. Sample Size Calculator for Comparing Two Independent Proportions 2023 [Available from: https://statulator.com/SampleSize/ss2P.html
  19. 19. Global Initiative for Chronic Obstructive Lung Disease 2025 Report. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD 2025 Report; 2024 [04.02.2025]. Available from: https://goldcopd.org/2025-gold-report/
  20. 20. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al.; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007 Feb;356(8):775–89. 10.1056/NEJMoa063070
  21. 21. Patel N. An update on COPD prevention, diagnosis, and management: The 2024 GOLD Report. Nurse Pract. 2024 Jun;49(6):29–36. 10.1097/01.NPR.0000000000000180
  22. 22. Stolz D, Barandun J, Borer H, Bridevaux PO, Brun P, Brutsche M, et al. Diagnosis, Prevention and Treatment of Stable COPD and Acute Exacerbations of COPD: the Swiss Recommendations 2018. Respiration. 2018;96(4):382–98. 10.1159/000490551
  23. 23. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987 Feb;106(2):196–204. 10.7326/0003-4819-106-2-196
  24. 24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83. 10.1016/0021-9681(87)90171-8
  25. 25. De Pietro C, Camenzind P, Sturny I, Crivelli L, Edwards-Garavoglia S, Spranger A, et al. Switzerland: Health System Review. Health Syst Transit. 2015;17, 4 .doi:2015;17(4):1-288.
  26. 26. Yin HL, Yin SQ, Lin QY, Xu Y, Xu HW, Liu T. Prevalence of comorbidities in chronic obstructive pulmonary disease patients: A meta-analysis. Medicine (Baltimore). 2017 May;96(19):e6836. 10.1097/MD.0000000000006836
  27. 27. Ladova K, Vlcek J, Vytrisalova M, Maly J. Healthy adherer effect - the pitfall in the interpretation of the effect of medication adherence on health outcomes. J Eval Clin Pract. 2014 Apr;20(2):111–6. 10.1111/jep.12095
  28. 28. Lindenauer PK, Dharmarajan K, Qin L, Lin Z, Gershon AS, Krumholz HM. Risk Trajectories of Readmission and Death in the First Year after Hospitalization for Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2018 Apr;197(8):1009–17. 10.1164/rccm.201709-1852OC
  29. 29. Ehteshami-Afshar S, Merchant N. The underappreciated role of documentation in improving COPD care. Cleve Clin J Med. 2022 May;89(5):249–51. 10.3949/ccjm.89a.21044
  30. 30. Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012 Nov;67(11):957–63. 10.1136/thoraxjnl-2011-201518
  31. 31. Rello J, Rodriguez A, Torres A, Roig J, Sole-Violan J, Garnacho-Montero J, et al. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J. 2006 Jun;27(6):1210–6. 10.1183/09031936.06.00139305
  32. 32. Lodise TP, Li J, Gandhi HN, O’Brien G, Sethi S. Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies. Int J Chron Obstruct Pulmon Dis. 2020 Nov;15:2889–900. 10.2147/COPD.S269637
  33. 33. Buess M, Schilter D, Schneider T, Maurer M, Borer H, Thurnheer R, et al. Treatment of COPD Exacerbation in Switzerland: Results and Recommendations of the European COPD Audit. Respiration. 2017;94(4):355–65. 10.1159/000477911
  34. 34. Amin AN, Cornelison S, Woods JA, Hanania NA. Managing hospitalized patients with a COPD exacerbation: the role of hospitalists and the multidisciplinary team. Postgrad Med. 2022 Mar;134(2):152–9. 10.1080/00325481.2021.2018257
  35. 35. Reis AJ, Alves C, Furtado S, Ferreira J, Drummond M, Robalo-Cordeiro C; GI DPOC-Grupo de Interesse na Doença Pulmonar Obstrutiva Crónica. COPD exacerbations: management and hospital discharge. Pulmonology. 2018;24(6):345–50. 10.1016/j.pulmoe.2018.06.006
  36. 36. Kim N, Teng W, Akande O, Rhodes D, Rochester CL. Impact of an Inpatient COPD Care Pathway on Hospital Care Process and Outcome Metrics. Chronic Obstr Pulm Dis (Miami). 2025 Jul;12(4):304–16. 10.15326/jcopdf.2024.0585

Most read articles by the same author(s)